Regeneron Pharmaceuticals Inc
NASDAQ:REGN

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Watchlist
Price: 746.5 USD 0.27%
Market Cap: 82B USD
Have any thoughts about
Regeneron Pharmaceuticals Inc?
Write Note

Relative Value

The Relative Value of one REGN stock under the Base Case scenario is 608.01 USD. Compared to the current market price of 746.5 USD, Regeneron Pharmaceuticals Inc is Overvalued by 19%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

REGN Relative Value
Base Case
608.01 USD
Overvaluation 19%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
60
vs Industry
49
Median 3Y
6.5
Median 5Y
6.4
Industry
7.7
Forward
5.7
vs History
53
vs Industry
6
Median 3Y
19.2
Median 5Y
18.4
Industry
22.2
Forward
16.3
vs History
49
vs Industry
7
Median 3Y
16.9
Median 5Y
19.3
Industry
22.3
vs History
46
vs Industry
6
Median 3Y
24.7
Median 5Y
20.9
Industry
25.5
vs History
98
vs Industry
21
Median 3Y
3.7
Median 5Y
3.9
Industry
2.5
vs History
66
vs Industry
42
Median 3Y
6
Median 5Y
5.9
Industry
7.8
Forward
5.2
vs History
66
vs Industry
39
Median 3Y
6.9
Median 5Y
6.8
Industry
9
vs History
41
vs Industry
5
Median 3Y
15
Median 5Y
15
Industry
3.9
Forward
13.2
vs History
38
vs Industry
4
Median 3Y
16.3
Median 5Y
16.3
Industry
3.6
Forward
14.1
vs History
50
vs Industry
7
Median 3Y
15.6
Median 5Y
17.8
Industry
5.2
vs History
58
vs Industry
5
Median 3Y
21.9
Median 5Y
23.5
Industry
3.3
vs History
96
vs Industry
32
Median 3Y
3.8
Median 5Y
3.8
Industry
4.6

Multiples Across Competitors

REGN Competitors Multiples
Regeneron Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.3B USD 5.9 17.7 16.1 17.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 888 840.5 -180 080 -218 674.5 -216 179.2
US
Abbvie Inc
NYSE:ABBV
314.4B USD 5.6 61.9 15.2 23.4
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.8 37.4 17.3 32.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117B USD 11 -243 24.4 25.6
US
Gilead Sciences Inc
NASDAQ:GILD
112.5B USD 4 892.3 9.8 9.8
US
Epizyme Inc
F:EPE
94.1B EUR 1 859.4 -474.5 -516.7 -502.9
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Seagen Inc
F:SGT
39.3B EUR 17.9 -54.9 -59 -53.2
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.6 -130.6 -105.1 -76.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
31.8B USD 15.2 -95.6 -227.4 -159.8
P/E Multiple
Earnings Growth
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Average P/E: 208.4
17.7
43%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 080 N/A
US
Abbvie Inc
NYSE:ABBV
61.9
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -243
42%
US
Gilead Sciences Inc
NASDAQ:GILD
892.3
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -474.5 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.9 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -130.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -95.6 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Average EV/EBITDA: 17.2
16.1
46%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -218 674.5 N/A
US
Abbvie Inc
NYSE:ABBV
15.2
28%
US
Amgen Inc
NASDAQ:AMGN
17.3
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.4
38%
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516.7 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -227.4 N/A
EV/EBIT Multiple
EBIT Growth
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Average EV/EBIT: 22.5
17.9
54%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 179.2 N/A
US
Abbvie Inc
NYSE:ABBV
23.4
88%
US
Amgen Inc
NASDAQ:AMGN
32.8
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.6
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -502.9 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -159.8 N/A

See Also

Discover More
Back to Top